https://mindmedicinelaw.com/briefing/compass-pathways-psilocybin-durability-data-implications-for-u-s-depression-trea-20260915-42146The Psychedelic Journalen2026-09-15T22:03:58.271298+00:00Compass Pathways’ Psilocybin Durability Data: Implications for U.S. Depression Treatment Policypsilocybin, compass pathways, depression, durability, fda approval, clinical trial, payer coverage, mental health, psychedelic therapy, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/usc-launches-clinical-study-on-meditation-in-psychedelic-therapy-20260915-41984The Psychedelic Journalen2026-09-15T15:07:16.895705+00:00USC Launches Clinical Study on Meditation in Psychedelic Therapyusc psychedelic trial, meditation and psychedelics, clinical protocols, set and setting, therapist training, psychedelic-assisted therapy, integration practices, clinical trial design, adverse events, regulatory implicationshttps://mindmedicinelaw.com/briefing/fda-s-2026-hearing-sets-new-standards-for-psychedelic-therapies-20260915-41981The Psychedelic Journalen2026-09-15T15:06:10.509785+00:00FDA’s 2026 Hearing Sets New Standards for Psychedelic Therapiesfda psychedelic standards, psychedelic therapy regulation, clinical trial requirements, mdma psilocybin lsd, therapist training standards, drug approval process, public health policy, market access psychedelics, post-market surveillancehttps://mindmedicinelaw.com/briefing/fda-issues-regulatory-framework-for-psychedelic-drug-sponsors-20260915-41982The Psychedelic Journalen2026-09-15T15:05:53.660749+00:00FDA Issues Regulatory Framework for Psychedelic Drug Sponsorsfda psychedelic framework, psychedelic clinical trials, drug approval process, therapist training requirements, safety monitoring psychedelics, policy implications psychedelics, psychedelic research compliance, mdma psilocybin regulationhttps://mindmedicinelaw.com/briefing/fda-hears-veterans-perspectives-on-psychedelic-ptsd-therapy-20260914-41983The Psychedelic Journalen2026-09-15T15:07:03.695020+00:00FDA Hears Veterans' Perspectives on Psychedelic PTSD Therapyfda hearing, veterans, psychedelic therapy, ptsd treatment, mdma, psilocybin, policy, clinical trials, patient testimony, regulatory processhttps://mindmedicinelaw.com/briefing/fda-schedules-public-hearing-on-psychedelics-for-depression-and-ptsd-20260914-41822The Psychedelic Journalen2026-09-14T22:05:05.596043+00:00FDA Schedules Public Hearing on Psychedelics for Depression and PTSDfda psychedelic hearing, psychedelic regulation us, depression ptsd psychedelics, mdma clinical trials, psilocybin policy, drug scheduling, expanded access, post-marketing surveillance, trump administration drug policyhttps://mindmedicinelaw.com/briefing/ohio-state-study-advances-psychedelic-therapy-for-ptsd-in-veterans-20260914-41662The Psychedelic Journalen2026-09-14T15:07:02.679054+00:00Ohio State Study Advances Psychedelic Therapy for PTSD in Veteransohio state university, psychedelic-assisted therapy, veterans, ptsd, clinical trials, public health, policy implications, midwest research, academic studieshttps://mindmedicinelaw.com/briefing/fda-accelerates-psychedelic-therapy-access-new-policy-roadmap-20260914-41661The Psychedelic Journalen2026-09-14T15:06:11.163770+00:00FDA Accelerates Psychedelic Therapy Access: New Policy Roadmapfda psychedelic policy, expanded access, psychedelic clinical trials, real-world evidence, patient access, regulatory oversight, mdma therapy, psilocybin research, controlled substances act, clinical trial designhttps://mindmedicinelaw.com/briefing/us-fda-psychedelic-approvals-impacts-on-japanese-pharmacy-policy-20260913-41867The Psychedelic Journalen2026-09-15T15:06:44.957854+00:00US FDA Psychedelic Approvals: Impacts on Japanese Pharmacy Policyus fda psychedelic approval, japan pharmacy policy, ibogaine regulation japan, pmda drug scheduling, cyp2d6 pharmacogenomics, psychedelic counseling japan, treatment-resistant depression, drug interaction management, international regulatory pressurehttps://mindmedicinelaw.com/briefing/fda-withholds-approval-phase-3-psilocybin-mdma-trials-in-us-psychiatry-20260913-41905The Psychedelic Journalen2026-09-15T15:06:27.497722+00:00FDA Withholds Approval: Phase 3 Psilocybin, MDMA Trials in US Psychiatrypsilocybin phase 3 trial, mdma fda rejection, psychedelic-assisted therapy, clinical trial methodology, psychiatric drug approval, depression treatment research, ptsd clinical trials, regulatory policy, long-term safety, therapist training standardshttps://mindmedicinelaw.com/briefing/suicidality-in-psychosis-risk-youth-depression-not-psychosis-drives-risk-20260911-41868The Psychedelic Journalen2026-09-15T15:07:35.473903+00:00Suicidality in Psychosis-Risk Youth: Depression, Not Psychosis, Drives Risksuicidal ideation, psychosis risk, depression, cannabis use, clinical trials, youth mental health, psychedelic research, public health policy, socio-occupational functioninghttps://mindmedicinelaw.com/briefing/psychedelic-use-and-pro-environmental-attitudes-in-uk-cohorts-20260911-41708The Psychedelic Journalen2026-09-14T22:07:11.304928+00:00Psychedelic Use and Pro-Environmental Attitudes in UK Cohortspsychedelic use, pro-environmental attitudes, vegetarian diet, psilocybin, LSD, UK cohort study, observational research, behavioral correlates, public health, psychedelic policyhttps://mindmedicinelaw.com/briefing/cardiac-interoception-measures-challenged-by-new-computational-model-20260911-41745The Psychedelic Journalen2026-09-14T22:06:52.842937+00:00Cardiac Interoception Measures Challenged by New Computational Modelcardiac interoception, bayesian belief updating, psychedelic clinical trials, computational modeling, heart rate discrimination, mind-body research, mechanistic endpoints, subjective experience, regulatory implicationshttps://mindmedicinelaw.com/briefing/temporal-rt-dynamics-in-bdiat-predict-suicidality-implications-for-psychedelic-t-20260911-41761The Psychedelic Journalen2026-09-14T22:06:37.846032+00:00Temporal RT Dynamics in BDIAT Predict Suicidality: Implications for Psychedelic Trialssuicide risk assessment, brief death implicit association test, reaction time dynamics, psychedelic clinical trials, behavioral markers, digital phenotyping, patient safety, regulatory guidance, clinical trial screeninghttps://mindmedicinelaw.com/briefing/ketamine-and-esketamine-for-suicidal-ideation-clinical-evidence-and-challenges-u-20260911-41760The Psychedelic Journalen2026-09-14T22:06:07.040348+00:00Ketamine and Esketamine for Suicidal Ideation: Clinical Evidence and Challenges (US, 2026)ketamine, esketamine, suicidal ideation, depression, clinical trials, fda, acute intervention, standardized measures, psychiatric risk, real-world outcomeshttps://mindmedicinelaw.com/briefing/esketamine-lowers-postoperative-anxiety-depression-in-colorectal-surgery-new-rct-20260911-41756The Psychedelic Journalen2026-09-14T22:05:47.497497+00:00Esketamine Lowers Postoperative Anxiety/Depression in Colorectal Surgery: New RCT Evidenceesketamine, perioperative mental health, colorectal cancer surgery, hospital anxiety and depression scale, randomized controlled trial, postoperative depression, ketamine, anesthesia, patient satisfaction, clinical researchhttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-closeness-predicts-social-anxiety-outcomes-20260911-41729The Psychedelic Journalen2026-09-14T22:05:26.156788+00:00MDMA-Assisted Therapy: Closeness Predicts Social Anxiety Outcomesmdma-assisted therapy, therapeutic alliance, social anxiety disorder, psychedelic psychotherapy, therapist training, clinical trial design, interpersonal closeness, process outcomes, self-transcendent emotions, psychedelic researchhttps://mindmedicinelaw.com/briefing/psilocybin-restores-memory-not-neural-synchrony-in-alzheimer-s-rats-20260910-41748The Psychedelic Journalen2026-09-14T22:06:22.640519+00:00Psilocybin Restores Memory, Not Neural Synchrony, in Alzheimer's Ratspsilocybin, alzheimer's disease, neural synchrony, spatial memory, preclinical research, rat model, fronto-hippocampal, translational neuroscience, behavioral endpoints, electrophysiologyhttps://mindmedicinelaw.com/briefing/fda-s-psychedelic-drug-framework-us-regulatory-pathways-clarified-20260910-41659The Psychedelic Journalen2026-09-14T15:05:26.333369+00:00FDA's Psychedelic Drug Framework: US Regulatory Pathways Clarifiedfda psychedelic framework, psychedelic drug regulation, clinical trial design, post-market surveillance, investigational new drug, psychological support protocols, policy implications, psychedelic therapy approval, us drug regulation, expanded access programshttps://mindmedicinelaw.com/briefing/music-therapy-as-adjunct-in-community-sud-care-pilot-insights-20260901-41486The Psychedelic Journalen2026-09-14T15:08:01.538737+00:00Music Therapy as Adjunct in Community SUD Care: Pilot Insightsmusic therapy, substance use disorder, community-based treatment, craving reduction, EEG biomarkers, psychometric measures, adjunctive interventions, pilot study, affective processing, clinical trialshttps://mindmedicinelaw.com/briefing/patterns-of-psychedelic-use-in-italy-insights-from-2025-survey-20260901-41482The Psychedelic Journalen2026-09-14T15:07:50.099728+00:00Patterns of Psychedelic Use in Italy: Insights from 2025 Surveypsychedelic use italy, global psychedelic survey, polysubstance exposure, public health, non-clinical motivations, alcohol reduction, tobacco reduction, policy implications, cross-sectional survey, harm reduction